Pamrevlumab (FG-3019), a fully human monoclonal antibody targeting CTGF, has led to reductions in fibrosis and improvements in function in skeletal and cardiac muscle in preclinical models of DMD. This evidence concerns the gene CCN2 and Duchenne muscular dystrophy.